Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THC KISS is a brand of cannabis-infused products developed and manufactured by THC BioMed, a licensed producer under Canada's Cannabis Act. The product line is most notable for its flagship 'Beverage Shot,' as well as biscuits and gummies, all formulated to contain a standardized dose of 10mg of Delta-9-tetrahydrocannabinol (THC) per unit. THC, the primary psychoactive constituent of cannabis, functions as a partial agonist at the G protein-coupled Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). Binding to CB1 receptors in the central nervous system inhibits the release of various neurotransmitters, including glutamate and GABA, which mediates the drug's analgesic, antiemetic, and psychotropic effects. THC KISS products are marketed in the Canadian legal cannabis market for both recreational use and the management of medical symptoms such as chronic pain and nausea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on THC KISS.